Sandoz Bio 100 targets 30%+ EBITDA margin by 2040
Sandoz’s Bio 100 plans expand its biosimilar portfolio to over 100 assets by 2040, targeting more than doubling net sales by 2035 and a core EBITDA margin above 30%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.